Alterity Therapeutics Limited Stock Nasdaq
Stocks
ATHE
US02155X2053
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.415 USD | -1.78% |
|
-2.75% | +43.34% |
| Market Cap | 83.21M 72.34M 67.33M 61.82M 117M 7.94B 119M 794M 311M 3.95B 313M 306M 13.26B | P/E 2026 * |
-0.32x | P/E 2027 * | -0.32x |
|---|---|---|---|---|---|
| Enterprise Value | 38.02M 33.05M 30.76M 28.25M 53.34M 3.63B 54.17M 363M 142M 1.81B 143M 140M 6.06B | EV / Sales 2026 * |
14.8x | EV / Sales 2027 * | 35.3x |
| Free-Float |
91.81% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Limited
| 1 day | -1.78% | ||
| 1 week | -2.75% | ||
| 1 month | -19.14% | ||
| 3 months | -6.56% | ||
| 6 months | +39.27% | ||
| Current year | +43.34% |
| 1 week | 4.2 |  | 4.78 |
| 1 month | 4.2 | | 5.89 |
| Current year | 3.02 | | 5.89 |
| 1 year | 2.66 | | 5.89 |
| 3 years | 1 | | 7 |
| 5 years | 1 | | 18.2 |
| 10 years | 1 | | 66.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
Abby Macnish
DFI | Director of Finance/CFO | - | 30/09/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.78% | -2.75% | - | - | 83.21M | |
| -1.40% | +2.59% | -1.71% | +11.28% | 48.53B | |
| -2.41% | -0.90% | +411.96% | +495.33% | 39.87B | |
| -1.16% | +12.96% | +28.81% | +7.25% | 38.68B | |
| -1.88% | -3.03% | +5.69% | +53.00% | 35.13B | |
| -1.74% | +5.12% | +14.44% | +41.77% | 29.79B | |
| -0.21% | -4.04% | +36.40% | +125.75% | 16.11B | |
| -2.85% | -3.92% | - | - | 16.08B | |
| -0.64% | +2.65% | +3.40% | +13.11% | 13.61B | |
| -1.19% | -1.32% | -1.73% | -34.37% | 12.62B | |
| Average | -1.53% | +1.05% | +62.16% | +89.14% | 27.82B | |
| Weighted average by Cap. | -1.60% | +2.03% | +79.78% | +108.61% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.57M 2.23M 2.08M 1.91M 3.6M 245M 3.66M 24.5M 9.61M 122M 9.65M 9.43M 409M | 1.2M 1.04M 971K 892K 1.68M 115M 1.71M 11.45M 4.49M 57.04M 4.51M 4.41M 191M |
| Net income | -14.64M -12.73M -11.85M -10.88M -20.54M -1.4B -20.86M -140M -54.81M -696M -55M -53.79M -2.33B | -29.66M -25.78M -24M -22.03M -41.61M -2.83B -42.25M -283M -111M -1.41B -111M -109M -4.73B |
| Net Debt | -45.19M -39.28M -36.56M -33.57M -63.39M -4.31B -64.38M -431M -169M -2.15B -170M -166M -7.2B | -40.88M -35.54M -33.08M -30.37M -57.35M -3.9B -58.24M -390M -153M -1.94B -154M -150M -6.51B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/07/26 | $4.415 | -1.78% | 3,794 |
| 30/07/26 | $4.495 | +1.24% | 9,533 |
| 29/07/26 | $4.440 | -2.74% | 2,151 |
| 28/07/26 | $4.565 | -2.14% | 2,211 |
| 27/07/26 | $4.665 | +2.75% | 3,895 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
- ATHE Stock
Select your edition
All financial news and data tailored to specific country editions
